Soliris has been approved in China for the treatment of adult patients with neuromyelitis optica spectrum disorder, or NMOSD, who are anti-aquaporin-4 antibody positive, AstraZeneca announced. “Soliris is the first and only complement inhibitor approved for the treatment of NMOSD in China,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- Unusually active option classes on open October 18th
- Johnson & Johnson (NYSE:JNJ) Slips despite Cancer Drug Win
- AstraZeneca data removes ‘slight overhang’ on Gilead, says Jefferies
- AstraZeneca price target raised to 13,200 GBp from 12,900 GBp at Guggenheim
- AstraZeneca call volume above normal and directionally bullish